Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12345678910111213...858859»
  • ||||||||||  Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin, Ilaris (canakinumab) / Novartis
    Trial primary completion date:  Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA (clinicaltrials.gov) -  Jan 10, 2025   
    P1/2,  N=41, Recruiting, 
    Trial primary completion date: Dec 2024 --> Mar 2025 Trial primary completion date: Dec 2024 --> Mar 2025
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Allosteric CDC37 inhibitor disrupts chaperone complex to block CDK4/6 maturation. (Pubmed Central) -  Jan 10, 2025   
    Furthermore, DDO-6079 decreased the thermostability of CDK6, reversed the resistance of CDK6 to palbociclib (a successful CDK4/6 inhibitor) in colorectal cancer cells and exhibited efficacy in vivo. Together, the results revealed that DDO-6079 is a first-in-class small molecule CDC37 inhibitor that disrupts the HSP90-CDC37-kinase chaperone complex and provides a new way to block kinase maturation.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  A genome-wide CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance (Pubmed Central) -  Jan 9, 2025   
    Our observation provided the first evidence of SEMA3F as a regulator of sensitivity to CDK4/6 inhibitors in breast cancer. The detailed mechanisms of resistance deserve further functional studies to develop the better strategy to overcome resistance in CDK4/6 inhibitors.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  SUNRISE: Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (clinicaltrials.gov) -  Jan 9, 2025   
    P3,  N=124, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> Mar 2025 Recruiting --> Active, not recruiting | N=207 --> 124 | Trial completion date: Dec 2025 --> Mar 2025 | Trial primary completion date: Sep 2025 --> Mar 2025
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Trial completion date, Trial primary completion date:  Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (clinicaltrials.gov) -  Jan 9, 2025   
    P1,  N=100, Recruiting, 
    Recruiting --> Active, not recruiting | N=207 --> 124 | Trial completion date: Dec 2025 --> Mar 2025 | Trial primary completion date: Sep 2025 --> Mar 2025 Trial completion date: May 2028 --> Feb 2028 | Trial primary completion date: May 2027 --> Feb 2027
  • ||||||||||  omecamtiv mecarbil (AMG 423) / Amgen, Servier, danicamtiv (MYK-491) / BMS
    Journal:  Differential effects of myosin activators on myocardial contractile function in non-failing and failing human hearts. (Pubmed Central) -  Jan 8, 2025   
    Although these effects were less pronounced with DN compared to OM in failing myocardium, DN impaired contractile properties in failing myocardium that were not affected in donor myocardium. Our results indicate that similar to first-generation myosin activators, the DN-induced slowing of cross-bridge kinetics may result in a prolongation of systolic ejection and delayed diastolic relaxation in the heart failure setting.
  • ||||||||||  Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
    Trial completion date, Trial primary completion date:  PBA Use for Treatment of ATF6-/- Patients (clinicaltrials.gov) -  Jan 8, 2025   
    P1,  N=2, Not yet recruiting, 
    Additionally, patients treated with denosumab developed MRONJ significantly earlier. Trial completion date: May 2025 --> May 2027 | Trial primary completion date: May 2025 --> May 2027
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    New trial:  NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL (clinicaltrials.gov) -  Jan 8, 2025   
    P=N/A,  N=1220, Not yet recruiting, 
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  NATIENS: Optimal Management and Mechanisms of SJS/TEN (clinicaltrials.gov) -  Jan 7, 2025   
    P3,  N=2, Terminated, 
    Clinical Trial Registration Number: NCT06613100 The abstract will be released to the public on February 10, 2025 at 2:00 PM PST N=150 --> 2 | Trial completion date: Aug 2028 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Jan 2025; Study is being terminated early due to difficultly in patient recruitment.
  • ||||||||||  Prolia (denosumab) / Amgen
    Clinical, Journal:  Possible role of bone turnover markers in the diagnosis of adult hypophosphatasia. (Pubmed Central) -  Jan 6, 2025   
    In this multicenter study, we enrolled 23 adult patients with a diagnosis of HPP and compared them with 46 osteoporotic subjects previously treated with zoledronic acid or denosumab. Similar results were confirmed when including male HPP patients, when adjusting for age and sex, and finally when performing a sensitivity analysis only in patients with ALP less than or equal to 32
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Development and Characterization of Palbociclib-Loaded PLGA Nanobubbles for Targeted Cancer Therapy. (Pubmed Central) -  Jan 6, 2025   
    Palbociclib showed limited activity in histology-agnostic CDK4- or CDK6-amplified tumors, though CNS tumors may be worthy of future investigation. The significant findings of this study emphasize the potential of palbociclib-loaded nanobubbles as a promising therapeutic system for improved breast cancer treatment.
  • ||||||||||  Trial completion date, Trial primary completion date:  FREE: De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease (clinicaltrials.gov) -  Jan 6, 2025   
    P4,  N=148, Enrolling by invitation, 
    Compared to conventional filgrastim mobilization, the combination of pegfilgrastim and filgrastim schedule has high efficacy, non-inferior safety, and superior health economic benefits during auto-HSCT. Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
  • ||||||||||  tolimidone (MTX228) / Bukwang Pharma, Biodexa Pharma
    Enrollment open:  An Adaptive Design Study of MTX228 (clinicaltrials.gov) -  Jan 6, 2025   
    P2,  N=24, Recruiting, 
    Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026 Not yet recruiting --> Recruiting
  • ||||||||||  Prolia (denosumab) / Amgen
    Assessment Of Clinical Approaches To Bone Health And Quality Of Life After Treatment In An Italian Cohort Of Breast Cancer Survivors (Exhibition hall) -  Jan 4, 2025 - Abstract #ESGO2025ESGO_1737;    
    At enrolment, only 7.7% of patients received antiresorptive therapy, increasing to 48.3% post-intervention, with Denosumab as the leading treatment...Despite guidelines, there is a lack of coordinated care, resulting in delayed osteoporosis interventions as well as diverse treatment approaches. A dedicated bone health pathway within post-menopausal BC survivors' oncological care is required to improve patient outcomes and QoL.
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial completion date, Trial primary completion date:  Panitumumab-IRDye800 in Diagnosing Participants with Malignant Glioma Undergoing Surgery (clinicaltrials.gov) -  Jan 3, 2025   
    P1/2,  N=22, Recruiting, 
    Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Dec 2025
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Journal:  Effects of Teprotumumab on Eyelid Retraction in Thyroid Eye Disease. (Pubmed Central) -  Jan 3, 2025   
    Teprotumumab treatment improves upper and lower eyelid retraction. The improvement in MRD correlated positively with proptosis reduction, indicating the influence of globe position on eyelid position.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Progress in the treatment of giant cell tumors of extremities with pathological fracture (Pubmed Central) -  Jan 3, 2025   
    RANKL inhibitors such as denosumab may be recommended if surgery is not possible or before performing resection. This article summarizes the common treatment modalities of pathological fractures combined with giant cell tumors of extremities, including the current status of surgical and pharmacological treatments, analyzing the choice of surgical modalities in different clinical situations, in order to provide clinical inspirations for diagnosis and treatment.
  • ||||||||||  Review, Journal:  Statin alternatives for the treatment of hypercholesterolemia - a safety evaluation. (Pubmed Central) -  Jan 3, 2025   
    Bempedoic acid is associated with a small increase in plasma uric acid and slightly increased frequency of episodes of gout in susceptible subjects. The cost and availability and the degree of lowering of LDL-C required are more likely to determine the choice of statin alternatives than the safety issues.
  • ||||||||||  Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
    Journal:  Advances and challenges in RAS signaling targeted therapy in leukemia. (Pubmed Central) -  Jan 3, 2025   
    Despite these challenges, new approaches have generated optimism about targeting specific RAS mutations in an allele-dependent manner for cancer therapy, supporting by compelling biochemical and structural evidence, which inspires further exploration of RAS allele-specific vulnerabilities. This review will discuss recent advances and challenges in the development of therapies targeting RAS signaling, highlight emerging therapeutic strategies, and emphasize the importance of allele-specific approaches for leukemia treatment.